Integrated proteogenomics analyses provide additional information regarding specific pathway activation e.g., ERBB2, and the consequent efficacy of inhibition therapy20, as well as an additional depth in tumor classification and biomarker selection21–23. Here, ERBB2 is linked to neoplasm.